Clearside Biomedical (CLSD) Receives a Hold from Needham
July 26 2022 - 11:16AM
TipRanks
In a report released today, Serge Belanger from Needham maintained
a Hold rating on Clearside Biomedical (CLSD – Research Report). The
company's shares closed last Tuesday at $1.59, close to its 52-week
low of $1.26. According to TipRanks.com, Belanger is a 3-star
analyst with an average return of 1.6% and a 42.9% success rate.
Belanger covers the Healthcare sector, focusing on stocks such as
Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and
KalVista Pharmaceuticals. Currently, the analyst consensus on
Clearside Biomedical is a Strong Buy with an average price target
of $9.67.
https://www.tipranks.com/news/blurbs/clearside-biomedical-clsd-receives-a-hold-from-needham-4?utm_source=advfn.com&utm_medium=referral
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Dec 2022 to Jan 2023
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Jan 2022 to Jan 2023